Things are looking pretty good for Paratek Pharmaceuticals Inc., a Boston-based biopharmaceutical company that has a huge presence in King of Prussia.
The federal agency granted marketing clearance to Nuzyra, an antibiotic developed by Paratek (NASDAQ: PRTK) to treat adults with community-acquired bacterial pneumonia and acute skin and skin structure infections. Nuzyra, according to the company, is a modernized tetracycline that can be administered as a once-daily IV or in pill form, writes John George in the Philadelphia Business Journal.
Dr. Evan Loh, who is the company’s president, chief operating officer and chief medical officer and based in King of Prussia, said the approvals are the first steps in an exciting time for Paratek, patients and physicians.
“In the face of ever-increasing antibiotic resistance, We are excited to bring to physicians an effective, well-tolerated monotherapy option for patients,” said Dr. Evan Loh. “Nuzyra offers clinicians the ability to treat patients with the IV and transition them home to complete treatment with the oral formulation. This potentially helps reduce hospitalizations and the costs associated with hospital stays.”
To read the complete story click here.